Pipeline

Our aim is to develop the right antibody for the right target, ultimately producing a treatment that is safer and more effective for patients with Alzheimer’s disease.

Sabirnetug (ACU193)

Sabirnetug is the first immunotherapy drug candidate to enter the clinic that was developed to selectively target toxic soluble amyloid beta oligomers (AβOs). As AβOs are an early trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration, sabirnetug addresses an underlying cause of Alzheimer’s by preventing toxic AβOs from binding to dendritic spines and helping preserve neuronal function.

8-year

collaboration with Merck
(Acumen holds exclusive rights of sabirnetug)

$3.6 million

Awarded a competitive $3.6 million U01 grant from National Institute of
Aging in 2017.

IPO
July 2021

ticker ABOS

Phase 1

Enrollment Complete

Phase 2

Initiation 1H 2024

Phase 3

Planning

Submission

Planning

Approval

Planning

ALTITUDE-AD

This study is a Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous sabirnetug (ACU193) in Early Alzheimer’s Disease